New Drug Approvals Down
Spending on medicines is down and the number of new drugs reaching the market is declining as well. No one wants to acknowledge the while a cautious FDA is part of the problem the overarching challenge facing industry -- and us -- is just how new all the targets current drug development targets are and how difficult it will be to personalize or tailor treatments to specific groups of patients. And the tools for doing so and improving the preventive capacity of next generation drugs will be snatched from companies if the industry's enemies get their way and blow up the Critical Path before it even gets started. The campaign of disinformation regarding the goals of the Critical Path and the science behind still shocks me. The ideological hatred borders on a psychological disturbance.